Marloes G J van Dongen - JoVE Visualize

Showing results (1-10 of 9) with videos related to

Pageof 1

Sort By:

Journal of Pharmacokinetics and Pharmacodynamics|October 2, 2019

Mathematical modeling of the glucagon challenge testSaeed Masroor, Marloes G J van Dongen, Ricardo Alvarez-Jimenez, et al.

Clinical Pharmacokinetics|October 8, 2020

Clinical Pharmacokinetics and Pharmacodynamics of the Cyclin-Dependent Kinase 4 and 6 Inhibitors Palbociclib, Ribociclib, and AbemaciclibStefanie L Groenland, Alejandra Martínez-Chávez, Marloes G J van Dongen, et al.

Journal of Clinical Pharmacology|September 9, 2014

First proof of pharmacology in humans of a novel glucagon receptor antisense drugMarloes G J van Dongen, Bart F Geerts, Erin S Morgan, et al.

Journal of Dietary Supplements|March 22, 2012

Hydrolyzed casein decreases postprandial glucose concentrations in T2DM patients irrespective of leucine contentBart F Geerts, Marloes G J van Dongen, Baukje Flameling, et al.

Gynecologic Oncology|April 1, 2022

Efficacy and safety of pembrolizumab for patients with previously treated advanced vulvar squamous cell carcinoma: Results from the phase 2 KEYNOTE-158 studyRonnie Shapira-Frommer, Linda Mileshkin, Ludmila Manzyuk, et al.

Clinical Pharmacology and Therapeutics|October 21, 2021

Effects of the Moderate CYP3A4 Inhibitor Erythromycin on the Pharmacokinetics of Palbociclib: A Randomized Crossover Trial in Patients With Breast CancerLaura Molenaar-Kuijsten, C Louwrens Braal, Stefanie L Groenland, et al.

The Lancet. Gastroenterology & Hepatology|February 3, 2022

Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 studyAurelien Marabelle, Philippe A Cassier, Marwan Fakih, et al.

Nature Cancer|April 10, 2023

PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trialLeonie Voorwerk, Olga I Isaeva, Hugo M Horlings, et al.

Nature Medicine|September 16, 2024

Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trialIris Nederlof, Olga I Isaeva, Manon de Graaf, et al.

Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:

Pageof 1

Journal of Pharmacokinetics and Pharmacodynamics|October 2, 2019

Mathematical modeling of the glucagon challenge testSaeed Masroor, Marloes G J van Dongen, Ricardo Alvarez-Jimenez, et al.

Clinical Pharmacokinetics|October 8, 2020

Clinical Pharmacokinetics and Pharmacodynamics of the Cyclin-Dependent Kinase 4 and 6 Inhibitors Palbociclib, Ribociclib, and AbemaciclibStefanie L Groenland, Alejandra Martínez-Chávez, Marloes G J van Dongen, et al.

Journal of Clinical Pharmacology|September 9, 2014

First proof of pharmacology in humans of a novel glucagon receptor antisense drugMarloes G J van Dongen, Bart F Geerts, Erin S Morgan, et al.

Journal of Dietary Supplements|March 22, 2012

Hydrolyzed casein decreases postprandial glucose concentrations in T2DM patients irrespective of leucine contentBart F Geerts, Marloes G J van Dongen, Baukje Flameling, et al.

Gynecologic Oncology|April 1, 2022

Efficacy and safety of pembrolizumab for patients with previously treated advanced vulvar squamous cell carcinoma: Results from the phase 2 KEYNOTE-158 studyRonnie Shapira-Frommer, Linda Mileshkin, Ludmila Manzyuk, et al.

Clinical Pharmacology and Therapeutics|October 21, 2021

Effects of the Moderate CYP3A4 Inhibitor Erythromycin on the Pharmacokinetics of Palbociclib: A Randomized Crossover Trial in Patients With Breast CancerLaura Molenaar-Kuijsten, C Louwrens Braal, Stefanie L Groenland, et al.

The Lancet. Gastroenterology & Hepatology|February 3, 2022

Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 studyAurelien Marabelle, Philippe A Cassier, Marwan Fakih, et al.

Nature Cancer|April 10, 2023

PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trialLeonie Voorwerk, Olga I Isaeva, Hugo M Horlings, et al.

Nature Medicine|September 16, 2024

Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trialIris Nederlof, Olga I Isaeva, Manon de Graaf, et al.

Pageof 1